AQEMIA continues to grow at a fast pace to discover new drugs with their generative AI fueled by deep physics. After raising €30M last year, the tech-enabled drug discovery company AQEMIA announces a €30M extension, bringing the Series A up to €60M. This investment is led by Wendel Growth, followed by historical investors Bpifrance through its Large Venture fund, Eurazeo and Elaia.

Aqemia raises €30 million in a Series A funding round led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of Elaia its historic investor. This financing will further support Aqemia’s core mission: to massively scale drug discovery, through a first-in-class technological platform combining quantum- inspired physics and machine learning.

Sacha Loiseau, Ph.D., Venture Partner at Elaia declares: “Aqemia’s technology to predict affinity between drug candidates and therapeutic targets has the clear potential to change the drug discovery paradigm and to thus have a major impact on the success rate of the entire drug development process. This is in strong adequation with Elaia’s strategy for the PSL Innovation Fund to invest in early-stage companies with disruptive technologies. We’re excited to be the first investor backing Aqemia and look forward to what lies ahead.”